Estudo da mutação do recetor do fator de crescimento epidérmico, durante 5 anos, numa população de doentes com cancro do pulmão de não pequenas células-Reference-Cited by-同舟云学术

Estudo da mutação do recetor do fator de crescimento epidérmico, durante 5 anos, numa população de doentes com cancro do pulmão de não pequenas células

Published:2013-01 Issue:1 Volume:19 Page:7-12
ISSN:0873-2159
Container-title:Revista Portuguesa de Pneumologia
language:pt
Short-container-title:Revista Portuguesa de Pneumologia

Author:

Castro A.S.,Parente B.,Gonçalves I.,Antunes A.,Barroso A.,Conde S.,Neves S.,Machado J.C.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference18 articles.

1. Estudo epidemiológico do cancro do pulmão em Portugal nos anos de 2000/2002;Parente;Rev Port Pneumol,2007

2. 3 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

3. EGFR mutations in lung cancer: correlation with clinical response to gef itinib therapy;Paez;Science,2004

4. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gef itinib treatment in patients with non-small-cell lung cancer with postoperative recurrence;Mitsudomi;J Clin Oncol,2005

5. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gef itinib and erlotinib;Pao;Proc Natl Acad Sci U S A,2004

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency and types of EGFR mutations in Moroccan patients with non–small cell lung cancer;Tumori Journal;2020-10-20

2. Solubilization, Hansen solubility parameters and apparent thermodynamic parameters of Osimertinib in (propylene glycol + water) cosolvent mixtures;Zeitschrift für Physikalische Chemie;2020-10-07

3. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative;BMC Pulmonary Medicine;2020-09-10

4. Solubility, solution thermodynamics and molecular interactions of osimertinib in some pharmaceutically useful solvents;Journal of Molecular Liquids;2019-06

5. Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice;PLOS ONE;2019-01-09